A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative

Health Technology Assessment

Volumn 7, Issue 4, 2003, Pages

  Chilcott, J ^a   Lloyd Jones, M ^a   Wight, J ^a   Forman, K ^a,b   Wray, J ^a,c   Beverley, C ^a   Tappenden, P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BP IMMUNO; MONOCLONAL RHESUS D ANTIBODY; POLYCLONAL RHESUS D ANTIBODY; RHESUS D ANTIBODY; RUBELLA VACCINE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANTEPARTUM HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEVELOPMENTAL DISORDER; DISABILITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG INHIBITION; DRUG MARKETING; DRUG PROGRAM; DRUG SAFETY; DRUG SENSITIZATION; ECONOMIC EVALUATION; ETHICS; FETOMATERNAL TRANSFUSION; FETUS DEATH; FOLLOW UP; HEALTH CARE POLICY; HEALTH ECONOMICS; HEART PALPITATION; HEMOLYSIS; HOT FLUSH; HUMAN; INFORMED CONSENT; INJECTION PAIN; LOW BIRTH WEIGHT; MATERNAL WELFARE; MEDICAL PRACTICE; META ANALYSIS; MIDWIFE; MOTHER FETUS RELATIONSHIP; NEWBORN DEATH; NEWBORN HEMOLYTIC DISEASE; NEWBORN JAUNDICE; PARENTAL BEHAVIOR; PATIENT EDUCATION; PRACTICE GUIDELINE; PREGNANCY; PRENATAL PERIOD; PRIMIGRAVIDA; PRION DISEASE; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; REVIEW; RHESUS ISOIMMUNIZATION; RISK ASSESSMENT; STILLBIRTH; TREATMENT FAILURE; TREATMENT OUTCOME; VAGINA BLEEDING; VIRUS INFECTION; VISUAL FIELD DEFECT;

EID: 0037281752     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7040     Document Type: Review

References (75)

1. Intelihealth: Merriam-Webster medical dictionary. 2002. URL: http://www.intelihealth.com/
2. Urbaniak SJ. The scientific basis of antenatal prophylaxis. British Journal of Obstetrics and Gynaecology 1998;105 Suppl 18:11-18.
3. Contreras M. The prevention of Rh haemolytic disease of the fetus and newborn - General background. British Journal of Obstetrics and Gynaecology 1998;105:7-10.
4. Lee D, Contreras M, Entwhistle CC, Forman KM, Fraser ID, Gascoigne EW, et al. Recommendations for the use of anti-D immunoglobulin. Prescribers' Journal 1991;31:137-45.
5. McSweeney E, Kirkham J, Vinall P, Flanagan P. An audit of anti-D sensitisation in Yorkshire. British Journal of Obstetrics and Gynaecology 1998;105:1091-4.
6. Crew L, Davies G, Farrall L, Gabra G, Gascoigne E, Slocombe G, et al. Preliminary report of an audit for failures of Rhesus prophylaxis programme in the West Midlands. British Journal of Obstetrics and Gynaecology 1998;105:37.
7. Howard H, Martlew VJ, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: Are the guidelines being adequately followed? British Journal of Obstetrics and Gynaecology 1997;104:37-41.
8. Vause S, Maresh M. Indicators of quality of antenatal care: A pilot study. British Journal of Obstetrics and Gynaecology 1999;106:197-205.
9. Vause S, Wray J, Bailie C. Management of women who are Rhesus D negative in Northern Ireland. Journal of Obstetrics and Gynaecology 2000;20:374-7.
10. Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. British Journal of Obstetrics and Gynaecology 1998;105:129-34.
11. Hughes RG, Craig JIO, Murphy WG, Greer IA. Causes and clinical consequences of Rhesus (D) haemolytic disease of the newborn: A study of a Scottish population, 1985-1990. British Journal of Obstetrics and Gynaecology 1998;105:38.
12. Hussey RM, Clarke CA. Deaths from Rh haemolytic disease in England and Wales in 1988 and 1989. British Medical Journal 1991;303:445-6.
13. Whitfield CR, Raafat A, Urbaniak SJ. Under-reporting of mortality from RhD haemolytic disease in Scotland and its implications: Retrospective review. British Medical Journal 1997;315:1504-5.
14. Murphy KW, Whitfield CR. Rhesus disease in this decade. Contemporary Reviews in Obstetrics 1994;6:61-7.
15. Office for National Statistics. Mortality Statistics: Childhood, Infant and Perinatal. Review of the Registrar General on deaths in England and Wales; 1999. Series (DH3, No. 32). London: The Stationery Office; 2001.
16. Schumacher B, Moise, KJ Jr. Fetal tranfusion for red blood cell alloimmunization in pregnancy. Obstetrics and Gynecology 1996;88:137-50.
17. Ulm B, Svolba G, Ulm MR, Bernaschek G, Panzer S. Male fetuses are particularly affected by maternal alloimmunization to D. Transfusion - Bethesda 1999(Feb);39:169-73.
18. Ouweland WH, Goodyear E, Camilleri-Ferrante C, Burgess G, Rankin A. Epidemiology of RhD haemolytic disease of the newborn in East Anglia. British Journal of Obstetrics and Gynaecology 1998;105:23-4.
19. Jacob SR, Scandrett-Hibdon S. Mothers grieving the death of a child. Case reports of maternal grief. Nurse Practitioner 1994;19(Pt 7):60-5.
20. Vance JC, Foster WJ, Najman JM, Embelton G, Thearle MJ, Hodgen FM. Early parental responses to sudden infant death, stillbirth or neonatal death. Medical Journal of Australia 1991;155:292-7.
21. Vance JC, Najman JM, Thearle MJ, Embelton G, Foster WJ, Boyle FM. Psychological changes in parents eight months after the loss of an infant from stillbirth, neonatal death, or suddent infant death syndrome - A longitudinal study. Pediatrics 1995;96:933-8.
22. Janssen HJEM, Cuisinier MCJ, De Graauw KPHM, Hoogduin KAL. A prospective study of risk factors predicting grief intensity following pregnancy loss. Archives of General Psychiatry 1997;54:56-61.
23. Zeanah CH, Dailey JV, Rosenblatt MJ, Saller DN. Do women grieve after terminating pregnancies because of fetal anomalies? A controlled investigation. Obstetrics and Gynecology 1993;82:270-5.
24. Kolker A, Burke BM. Grieving the wanted child: Ramifications of abortion after prenatal diagnosis of abnormality. Health Care for Women International 1993;14:513-26.
25. Brewaeys A. Review: Parent-child relationships and child development in donor insemination families. Human Reproduction Update 2001;7:38-46.
26. Durna EM, Bebe J, Leader, LR, Steigrad SJ, Garrett DG. Donor insemination: Effects on parents. Medical Journal of Australia 1995;163:248-51.
27. Baron, L, Blanco L, Valzacchi GR, Pasqualini S. Oocyte donation (OD) and donor insemination (DI): A comparative psychological study of parents and children. Fertility and Sterility 1998;70(Suppl):278S.
28. Craig JS, McClure, BG, Tubman TRJ. British Medical Journal 1998;316:1611.
29. Van Kamp IL, Klumpfer, FJ, Bakkum RSLA, Oepkes, D, Meerman RH, Scherjon SA, et al. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. American Journal of Obstetrics and Gynecology 2001;185:668-73.
30. Farina A, Calderoni P, Carinci P, Rizzo N. Survival analysis of transfused fetuses affected by Rhalloimmunization. Prenatal Diagnosis 2000;20:881-5.
31. Hudon L, Moise KJ Jr, Hegemier SE, Hill RM, Moise AA, Smith E O'B, et al. Long-term neuro-developmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. American Journal of Obstetrics and Gynecology 1998;179:858-63.
32. Janssens HM, De Haan MJ, Van Kamp IL, Brand, Kanhai HH, Veen S. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. Journal of Pediatrics 1997;131:373-80.
33. Van Zeben-Van Der Aa TM, Verlooeve-Vanhorick SP, Brand R, Ruys JH. Morbidity of very low birth-weight infants at corrected age of two years in a geographically defined population. Report from project on preterm and small for gestational age infants in the Netherlands. Lancet 1989;1:253-5.
34. Office for National Statistics. Birth statistics. Review of the Registrar General on Births and Patterns of Family Building in England and Wales; 1999 (FM1, No. 28). London: The Stationery Office; 1998.
35. Liptak GS, O'Donnell M, Conaway M, Chumlea WC, Wolrey G, Henderson RC, et al. Health status of children with moderate to severe cerebral palsy. Developmental Medicine and Child Neurology 2001;43:364-70.
36. Van Der Dussen L, Nieuwstraten W, Roebroeck M, Stam HJ. Functional level of young adults with cerebral palsy. Clinical Rehabilitation 2001;15:84-91.
37. Schwartz L, Engel JM, Jensen MP. Pain in persons with cerebral palsy. Archives of Physical Medicine and Rehabilitation 1999;80:1243-6.
38. Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. Journal of the American Medical Association 2000;284:850-6.
39. Bio Products Laboratory. The Clinical and Cost Effectiveness of Routine Antenatal Prophylaxis for Rhesus Negative Women in Pregnancy. Submission to the National Institute for Clinical Excellence. Burgess Hill UK: Schering Health Care Ltd; August 2001.
40. Baxter Healthcare Ltd. The Clinical and Cost Effectiveness of Anti-D Prophylaxis for Rhesus Negative Women in Pregnancy. Submission to the National Institute for Clinical Excellence. Newbury, Berkshire: Baxter Healthcare Ltd; August 2001.
41. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. CRD's Guidance for Those Carrying Out or Commissioning Reviews. CRD Report No. 4 (2nd Edition). York: University of York, 2001.
42. Huchet J, Dallemagne S, Huchet C, Brossard Y, Larsen M, Parnet-Mathieu F. Application ante-partum du traitement preventif d'immunisation rhesus D chez les femmes rhesus negatif. Evaluation parallele des passages transplacentaire d'hematies foetales. Resultants d'une etude multicentrique menée en region Parisienne. [Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 1987;16:101-11.
43. MacKenzie IZ, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine antenatal Rhesus D immunoglobulin prophylaxis: The results of a prospective 10 year study. British Journal of Obstetrics and Gynaecology 1999;106:492-7.
44. Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfusion Medicine 1995;5:15-19.
45. Tovey LA, Townley A, Stevenson BJ, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983;2:244-6.
46. Mayne S, Parker JH, Harden TA, Dodds SD, Beale JA. Rate of RhD sensitisation before and after implementation of a community-based antenatal prophylaxis programme. British Medical Journal 1997;315:1588.
47. Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet 1997;350:185-6.
48. Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the quality of randomized trials: Reliability of the Jadad scale. Controlled Clinical Trials 1999;20:448-52.
49. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: Antenatal prophylaxis. Canadian Medical Association Journal 1978;118:623-7.
50. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks' gestation service program. Canadian Medical Association Journal 1978;118:627-30.
51. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: An analysis of the reasons for such failures. Transfusion Medicine Reviews 1987;1:101-12.
52. Trolle B. Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. Acta Obstetricia et Gynecologica Scandinavica 1989;68:45-7.
53. Hermann M, Kjellman H, Ljunggren C. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D. Acta Obstetrica et Gynecologica Scandinavica 1984;124(Suppl):1-15.
54. Thornton JG, Page C, Foote G, Arthur GR, Tovey LA, Scott JS. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. British Medical Journal 1989;298:1671-3.
55. Parsons ML, Van Den Hof MC, Armson BA, Coffey J, Liston RM, Peddle LJ, et al. A comparison of the rate of Rh (D) alloimmunisation between Nova Scotia and Scotland. British Journal of Obstetrics and Gynaecology 1998;105:39.
56. Baskett TF, Parsons ML. Prevention of Rh(D) alloimmunization: A cost-benefit analysis. Canadian Medical Association Journal 1990;142:337-9.
57. Vick S, Cairns J, Urbaniak SJ, Whitefield C, Rafaat A. An Economic Evaluation of Antenatal Anti-D Prophylaxis in Scotland. 1995; Health Economics Research Unit, University of Aberdeen, discussion paper 10/95.
58. Vick S, Cairns J, Urbaniak S, Whitefield C, Raafat A. Cost-effectiveness of antenatal anti-D prophylaxis. Health Economics 1996;5:319-28.
59. 0 (D) sensitization: A cost-effective analysis. Obstetrics and Gynecology 1982;59:477-80.
60. Torrance GW, Zipursky A. Cost-effectiveness of antepartum prevention of Rh immunization. Clinics in Perinatology 1984;11:267-81.
61. Adams MM, Marks JS, Koplan JP. Cost implications of routine antenatal administration of Rh immune globulin. American Journal of Obstetrics and Gynecology 1984;149:633-8.
62. Selinger M. The pharmacoeconomics of antenatal prophylaxis. In: Building on Success: Antenatal Prophylaxis. London: Bio Products Laboratory 1997. p. 6-7.
63. Association of Radical Midwives. The Clinical and Cost-Effectiveness of Anti-D Prophylaxis for RhD (Rhesus) Negative Women in Pregnancy. Submission to the National Institute for Clinical Excellence from the Association of Radical Midwives; 2001.
64. Meisel H, Reip A, Faltus B, Lu M, Porst H, Wiese M, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-11.
65. Foster PR, McIntosh RV, Welch AG. Hepatitis C infection from anti-D immunoglobulin. Lancet 1995;346:372-3.
66. Tabor E. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999;39:1160-8.
67. Turner ML, Ironside JW. New-variant Creutzfeld-Jakob disease: The risk of transmission by blood transfusion. Blood Reviews 1998;12:255-68.
68. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Reviews 2000;14:44-61.
69. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001;358:208-9.
70. Gilling-Smith C, Toozs-Hobson P, Potts DJ, Touquet R, Beard RW. Management of bleeding in early pregnancy in accident and emergency departments. British Medical Journal 1994;309:574-5.
71. Office for National Statistics. Birth Statistics. England and Wales; 1996 (FM1, No. 1). London: The Stationery Office; 1998.
72. Kitchen WH, Bowman E, Callanan C. The cost of improving the outcome for infants of birthweight 500-999 g in Victoria: The Victorian Infant Collaborative Study Group. Journal of Paediatrics and Child Health 2002;29:56-62.
73. Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. Journal of Paediatrics and Child Health 1997;33:202-8.
74. Stevenson RC, Pharaoh POD, Stevenson CJ, McCabe CJ, Cooke RWI. Cost of care for a geographically determined population of low birthweight infants to age 8-9 years. II. Children with disability. Archives of Disease in Childhood 1996;74:F118-23.
75. Congenital Disabilities (Civil Liability) Act. London: HMSO; 1976.